Ipsen reports satisfaction with 2010 growth

Ipsen has reported its satisfaction with the business growth and sales improvement it has experienced in the last year.

The pharmaceutical company has posted a 12-month consolidated group sales total of 1.03 billion euros (933.09 million pounds), representing an increase of five percent on 2009 in constant currency terms.

Strong growth was seen in its specialty care division, which accounted for 704.3 million euros of its overall total, with oncology and endocrinology drugs seeing high demand.

Other key developments taking place in 2010 include the decision by fellow pharmaceutical company Roche to return the rights for the drug taspoglutide to Ipsen.

Marc de Garidel, chairman and chief executive officer of the firm, said: "After many years in the biotechnology industry, I am very proud to lead Ipsen, now grown into an international specialty care biopharma."

This week, Ipsen also announced that its partner Inspiration Biopharmaceuticals has reported promising early-stage clinical data on IB1001, a new treatment for haemophilia B.